Physician profile
Imran Khan
NPI 1598045791
$2,157.63
in general payments reported to CMS, 2019-2025
36 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $300 · 2021: $221 · 2022: $476 · 2023: $509 · 2024: $201 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $316.52 | 2019-2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $275.89 | 2022-2023 | |
| Abbvie INC. | $236.53 | 2021-2023 | |
| Amgen INC. | $169.99 | 2019-2021 | |
| Kerecis Limited | $138.47 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Avion Pharmaceuticals | $83.76 | 2022-2023 | Dhivy |
| Pfizer INC. | $76.26 | 2023 | |
| Janssen Pharmaceuticals, INC | $69.14 | 2019-2021 | |
| Lilly USA, LLC | $67.51 | 2021-2023 | Mounjaro, Trulicity |
| Abbott Laboratories | $60.76 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $59.45 | 2025 | Opsumit |
| Astellas Pharma US INC | $52.30 | 2019 | |
| Optinose US, INC. | $45.47 | 2020 | |
| Corcept Therapeutics | $44.80 | 2024-2025 | Korlym |
| Springworks Therapeutics, INC. | $37.84 | 2024 | Ogsiveo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $34.02 | 2022 | |
| Horizon Therapeutics Plc | $33.10 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $31.78 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $28.32 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $22.57 | 2023 | Austedo |
| Neurelis, INC. | $22.25 | 2022 | |
| Ucb, INC. | $21.54 | 2023 | |
| Glaxosmithkline, LLC. | $20.22 | 2023 | Shingrix |
| Livanova USA, INC. | $18.80 | 2022 | |
| Impel Pharmaceuticals INC. | $18.53 | 2023 | Trudhesa |
| Life Molecular Imaging Ltd | $18.11 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.99 | 2022 | Tlando, Xyosted |
| Otsuka America Pharmaceutical, INC. | $17.29 | 2023 | Rexulti |
| Medtronic, INC. | $17.12 | 2023 | Closurefast |
| Insmed, INC. | $16.31 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.84 | 2022 | |
| Halozyme INC | $15.43 | 2023 | |
| Paratek Pharmaceuticals, INC. | $14.85 | 2025 | Nuzyra |
| Sunovion Pharmaceuticals INC. | $13.85 | 2019 | |
| Radius Health, INC. | $13.51 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.